E-Leviate is a newly developed, next-generation medical device designed to treat vaginal atrophy, genitourinary syndrome of menopause (GSM), pelvic organ prolapse (POP), urinary stress incontinence, and cystitis. E-Leviate Pharma Ltd leverages proprietary, IP-protected technology to deliver cutting-edge solutions in drug delivery and biomedical innovation.
At E-Leviate Pharma Ltd, our mission is to elevate care and improve outcomes through innovative, IP-protected drug delivery and biomedical technologies. Rooted in science and driven by compassion, we are committed to developing meaningful solutions that make a real difference in women’s health around the world.
The research and development phase successfully concluded with the identification and optimization of the drug’s core formulation, laying the foundation for further testing and development
Early-stage prototypes were tested for safety and tolerability. All results met internal benchmarks, indicating the formulation is safe for progressing to the next stage
The formulation is currently being tested in pre-clinical (animal) models to assess pharmacokinetics, safety, and drug release behavior in a biological environment
Work is underway to compile and submit an Investigational New Drug (IND) application to regulatory authorities, which is required before initiating human clinical trials
Preparing for Phase I human trials, with institutional ethics board approvals currently under review to ensure all safety and ethical guidelines are met.
The projected market launch depends on successful completion of clinical trials and regulatory approvals. Timing may vary based on trial results and compliance milestones
.png)
Partner with us at the forefront of biomedical innovation
E-Leviate is entering an exciting growth phase and seeking strategic investment to accelerate the development and commercialization of our patented slow drug delivery technologies. Our innovative medical devices target key health conditions such as vaginal atrophy, GSM, pelvic organ prolapse and more.
With a strong R&D foundation and scalable market potential, this is a unique opportunity to invest in a high-impact solution with significant global demand. Together, we can unlock exceptional commercial value and improve the quality of life for millions of women worldwide.
E-Leviate has completed its initial funding round, supporting vital R&D and clinical trials for our women's health drug delivery devices. We're now positioned to scale and bring innovative treatments to the global market.
We are now preparing for our Seed funding round to support:
This next stage is key to bringing our IP-protected technology to market and transforming care for millions of women worldwide.
We welcome strategic investors to join us in this pivotal phase of growth.